The use of hyaluronidase in the manufacturing of a drug for the treatment of conditions of interstitial edema in connection with organ grafting associated with an increased local content of hyaluronan in the connective tissue of a mammal. The drug comprises hyaluronidase in an amount giving a daily dosage of from 1 to 100,000 IU/kg body weight wh en given locally or systemically to a mammal. A method of treating conditions of interstitial edema in connection with organ grafti ng associated with an increased local synthesis of hyaluronan by systemic or local treatment with a pharmaceutical comprising hyaluronidase.< /SDOAB>
